Grampus Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 02-06-2024
- Paid Up Capital ₹ 0.75 M
as on 02-06-2024
- Company Age 23 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 2.80 M
as on 02-06-2024
- Revenue 1172.51%
(FY 2017)
- Profit -4700.78%
(FY 2017)
- Ebitda -1625.55%
(FY 2017)
- Net Worth -1704.58%
(FY 2017)
- Total Assets -11.00%
(FY 2017)
About Grampus Pharmaceuticals
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.75 M.
The company has closed loans amounting to ₹2.80 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Manav Maini, Pawan Maini, and Puneet Batra serve as directors at the Company.
- CIN/LLPIN
U24231HR2001PTC034631
- Company No.
034631
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Mar 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Ambala, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Grampus Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pawan Maini  | Managing Director | 05-Mar-2001 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manav Maini | Director | 17-Nov-2008 | Current |
| Puneet Batra | Director | 06-Dec-2006 | Current |
Financial Performance and Corporate Structure Insights of Grampus Pharmaceuticals.
Grampus Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 1172.51% increase. The company also saw a substantial fall in profitability, with a 4700.78% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1704.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Grampus Pharmaceuticals?
In 2017, Grampus Pharmaceuticals had a promoter holding of 94.67% and a public holding of 5.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 20 Oct 2008 | ₹0.30 M | Satisfied |
State Bank Of India Creation Date: 04 Jan 2008 | ₹0.20 M | Satisfied |
State Bank Of India Creation Date: 30 Jun 2007 | ₹0.30 M | Satisfied |
How Many Employees Work at Grampus Pharmaceuticals?
Unlock and access historical data on people associated with Grampus Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Grampus Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Grampus Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
